TORNALATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for TORNALATE (TORNALATE).
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
| Metabolism | Hepatic via sulfation and glucuronidation; also metabolized by catechol-O-methyltransferase (COMT). |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours. |
| Half-life | Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment. |
| Protein binding | Approximately 70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.4-2.1 L/kg, indicating extensive tissue distribution, particularly to the lungs. |
| Bioavailability | Inhalation: systemic bioavailability is about 20% due to pulmonary deposition and subsequent absorption; oral bioavailability is low (<5%) due to first-pass metabolism. |
| Onset of Action | Bronchodilation begins within 5-10 minutes following inhalation, with peak effect at 1-2 hours. |
| Duration of Action | Duration of bronchodilation is 8-12 hours, supporting twice-daily dosing for maintenance therapy. |
| Molecular Weight | 471.6 |
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific guidelines; caution in severe hepatic impairment due to lack of data. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Use with caution; initiate at lower end of dosing range due to potential for increased sensitivity. |
| 1st trimester | Insufficient human data; based on animal studies, potential risk of fetal harm cannot be ruled out. Use only if benefit outweighs risk. |
| 2nd trimester | Insufficient human data; based on animal studies, potential risk of fetal harm cannot be ruled out. Use only if benefit outweighs risk. |
| 3rd trimester | Insufficient human data; based on animal studies, potential risk of fetal harm cannot be ruled out. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for TORNALATE (TORNALATE).
| Placental transfer | Predicted to cross placenta based on molecular weight and pharmacokinetics; no specific human data. |
| Breastfeeding | No human data available; caution advised. Consider benefits of breastfeeding, risk of infant drug exposure, and risk of untreated maternal condition. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | TORNALATE (bitolterol mesylate) is a beta-2 adrenergic agonist. Limited human data; animal studies show no teratogenic effects at clinically relevant doses. First trimester: no known risk; second/third trimester: may cause fetal tachycardia, hypoglycemia, and hyperglycemia due to beta agonist activity. Risk of preterm labor and low birth weight with chronic use. Overall, consider risk-benefit; not a major teratogen. |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum glucose, and potassium levels. Assess fetal heart rate and growth via ultrasound if used chronically. Monitor for signs of preterm labor. Pulmonary function tests to assess asthma control. |
| Fertility Effects | No significant effects on fertility reported in animal studies. In humans, no specific data; beta-2 agonists are not known to impair fertility. Uncontrolled asthma may reduce fertility; thus, controlling asthma with TORNALATE may indirectly improve fertility. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to tornalate or any component of the formulation
| Precautions | Paradoxical bronchospasm, Cardiovascular effects (tachycardia, arrhythmias), Hypokalemia, Immediate hypersensitivity reactions |
| Food/Dietary | No known food interactions. Avoid excessive caffeine as it may potentiate stimulant effects. |
| Clinical Pearls | TORNALATE (bitolterol mesylate) is a selective beta-2 adrenergic agonist used as a bronchodilator. It has a faster onset than albuterol (within 3–5 minutes) but a shorter duration (3–5 hours). It is primarily indicated for acute bronchospasm in asthma or COPD. Caution in patients with cardiovascular disease, as it may cause tachycardia or arrhythmias. Not a first-line agent due to availability of longer-acting alternatives. Monitor for paradoxical bronchospasm and excessive dosing. |
| Patient Advice | Use only as directed for acute symptoms; do not exceed prescribed dose. · Rinse mouth after inhalation to prevent oral candidiasis. · Seek immediate medical help if symptoms worsen or you need more inhalations than usual. · Inform your doctor about any heart conditions, high blood pressure, or seizures. · Report side effects like chest pain, rapid heartbeat, or worsening breathing. |
Loading safety data…